Focal high-dose-rate brachytherapy: A dosimetric comparison of hemigland vs. conventional whole-gland treatment

被引:19
|
作者
Kamrava, Mitchell [1 ,2 ]
Chung, Melody P. [1 ]
Kayode, Oluwatosin [1 ]
Wang, Jason [1 ]
Marks, Leonard [3 ]
Kupelian, Patrick [1 ]
Steinberg, Michael [1 ,2 ]
Park, Sang-June [1 ]
Demanes, D. Jeffrey [1 ,2 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiat Oncol, Los Angeles, CA 90095 USA
[2] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA
关键词
Prostate; Focal therapy; Brachytherapy; LOCALIZED PROSTATE-CANCER; PHASE-II TRIAL; HDR BRACHYTHERAPY; RADICAL PROSTATECTOMY; RADIATION-THERAPY; FREE SURVIVAL; FOLLOW-UP; MONOTHERAPY; TOXICITY; CRYOABLATION;
D O I
10.1016/j.brachy.2012.09.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE: To determine the utility of focal high-dose-rate brachytherapy for localized prostate cancer, we investigated the impact on target coverage and dose to organs at risk (OARs) with hemigland (HG) compared with whole-gland (WG) treatment. METHODS AND MATERIALS: A total of 10 WG implants were used to generate 10 WG and 20 HG (left and right) treatment plans optimized with the inverse planning simulation annealing algorithm using Oncentra MasterPlan (Nucletron B.V., Veenendaal, The Netherlands). The standard distribution of 17-18 catheters designed for WG was used to generate HG plans. The same OARs namely bladder, rectum, and urethra contours and dose constraints were applied for HG and WG plans. The HG contour was a modification of the WG contour whereby the urethra divided the prostate into HGs. The prescription dose was 7.25 Gy x 6. Evaluated dose parameters were target dose D-90, V-100, and V-150 and D-0.1 (cc) D-1 and D-2 (cc) to OARs. RESULTS: The HG plans had a D-90, V-100, and V-150 to the HG target of 112%, 97.6%, and 33.8%, respectively. The WG plans had a D-90, V-100, and V-150 to the WG target of 108%, 98.8%, and 26.5%, respectively. The OAR D-2 (cc) doses were significantly lower in HG vs. WG plans: rectum (53.1% vs. 64.1%, p<0.0001), bladder (55.9% vs. 67.5%, p<0.0001), and urethra (69.3% vs. 95.2%, p<0.0001). CONCLUSIONS: In the present model, HG plans yielded a statistically significant decreased radiation dose to OARs and provided complete target coverage with a catheter array designed for WG coverage. The good dosimetry results obtained in this study support the feasibility of HG brachytherapy by using a subset of the WG catheter array. Catheter distribution and dosimetry refinements tailored to subtotal prostate brachytherapy should be explored to see if further improvements in dosimetry can be achieved. (C) 2013 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:434 / 441
页数:8
相关论文
共 50 条
  • [1] From whole gland to hemigland to ultra-focal high-dose-rate prostate brachytherapy: A dosimetric analysis
    Banerjee, Robyn
    Park, Sang-June
    Anderson, Erik
    Demanes, D. Jeffrey
    Wang, Jason
    Kamrava, Mitchell
    BRACHYTHERAPY, 2015, 14 (03) : 366 - 372
  • [2] Dosimetric comparison of targeted high-dose-rate brachytherapy versus whole gland treatment
    Chung, Melody P.
    Kayode, Oluwatosin
    Wang, Jason
    Park, Sang-June
    Marks, Leonard S.
    Demanes, D. Jeffrey
    Kamrava, Mitchell
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [3] Dosimetric Benefit of Hemi-Gland High Dose-Rate Prostate Brachytherapy Compared to Conventional Whole-Gland Treatment
    Park, S. J.
    Raince, J.
    Hagio, M. A.
    Kamrava, M.
    Demanes, D. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E258 - E259
  • [4] DOSIMETRIC COMPARISON BETWEEN PERMANENT VS. HIGH-DOSE-RATE PROSTATE BRACHYTHERAPY
    Frohlich, G.
    Major, T.
    Agoston, P.
    Lovey, J.
    Polgar, C.
    RADIOTHERAPY AND ONCOLOGY, 2009, 92 : S137 - S137
  • [5] Treatment planning comparison of high-dose-rate brachytherapy vs. robotic and conventional stereotactic body radiotherapy for ultrahypofractionated treatment of prostate cancer
    Yoshioka, Yasuo
    Sasamura, Kazuma
    Ito, Makoto
    Kaneko, Masahiro
    Takahashi, Taro
    Anno, Wataru
    Shimoyachi, Nana
    Suzuki, Junji
    Okuda, Takahito
    Kashihara, Tairo
    Inaba, Koji
    Igaki, Hiroshi
    Itami, Jun
    PHYSICS & IMAGING IN RADIATION ONCOLOGY, 2023, 26
  • [6] High Dose Rate (HDR) Brachytherapy vs. Helical Tomotherapy in the Treatment of Cervical Cancer: A Dosimetric Comparison
    Schultz, T. D.
    Kumar, T.
    Liu, Q.
    Bharucha, Z.
    Burmeister, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S791 - S792
  • [7] A dosimetric comparison of MammoSite high-dose-rate brachytherapy and Xoft Axxent electronic brachytherapy
    Dickler, Adam
    Kirk, Michael C.
    Seif, Neil
    Griem, Katherine
    Dowlatshahi, Kambiz
    Francescatti, Darius
    Abrams, Ross A.
    BRACHYTHERAPY, 2007, 6 (02) : 164 - 168
  • [8] A dosimetric comparison of two high-dose-rate brachytherapy planning systems in cervix cancer: Standardized template planning vs. computerized treatment planning
    Patone, Hassisen
    Souhami, Luis
    Parker, William
    Evans, Michael
    Duclos, Marie
    Portelance, Lorraine
    BRACHYTHERAPY, 2008, 7 (03) : 254 - 259
  • [9] Catheter displacements and dosimetric impact in focal salvage high-dose-rate prostate brachytherapy
    Moerland, M.
    van Son, M.
    Peters, M.
    Eppinga, W.
    Schokker, R.
    Lagendijk, J.
    van Zyp, J. van der Voort
    RADIOTHERAPY AND ONCOLOGY, 2021, 158 : S109 - S110
  • [10] A dosimetric comparison of MammoSite® and ClearPath high-dose-rate breast brachytherapy devices
    Dickler, Adam
    Seif, Nell
    Kirk, Michael C.
    Pate, Mita B.
    Bernard, Damian
    Coon, Alan
    Dowlatshahi, Kambiz
    Das, Rupak K.
    Patel, Rakesh R.
    BRACHYTHERAPY, 2009, 8 (01) : 14 - 18